Is it safe to use gadolinium-based contrast agents in MRI?

Area of Science:

• Radiology and Medical Imaging
• Nephrology
• Neurology

Background:

• Gadolinium-based contrast agents (GBCAs) have been crucial in magnetic resonance imaging (MRI) for three decades.
• Initial safety perceptions of GBCAs evolved with the discovery of nephrogenic systemic fibrosis (NSF) risks in patients with renal failure.
• Recent findings indicate gadolinium deposition in the brain, even with an intact blood-brain barrier.

Purpose of the Study:

• To review the historical development of gadolinium-based contrast agents.
• To discuss the established and emerging safety concerns associated with their use.
• To outline current recommendations and a precautionary approach advised by regulatory authorities.

Main Methods:

• Literature review of gadolinium-based contrast agent development.
• Analysis of studies on adverse events, including NSF and gadolinium deposition.
• Synthesis of regulatory guidance and expert recommendations.

Main Results:

• GBCAs have significantly enhanced MRI capabilities, particularly in neuroradiology.
• Nephrogenic systemic fibrosis is a known risk associated with GBCAs in patients with impaired renal function.
• Gadolinium deposition in the brain has been observed, with ongoing research into clinical significance.

Conclusions:

• While GBCAs are invaluable diagnostic tools, their use requires careful consideration of patient renal function.
• The long-term clinical impact of gadolinium deposition in the brain remains under investigation.
• A precautionary approach is recommended by regulatory bodies regarding GBCA administration.